Collaboration combines Monte Rosa Therapeutics’ highly differentiated QuEENTM discovery engine with Roche’s strong expertise in delivering transformative therapies to patients
Monte Rosa to receive an upfront payment of $50 million and potential future payments exceeding $2 billion
BOSTON, MA, USA I October 17, 2023 IMonte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced it has entered into a strategic collaboration and licensing agreement with global healthcare leader Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug.
“We are excited to partner with Roche, a leading healthcare and one of the world’s top oncology companies. Our QuEEN™ discovery engine, a highly validated and industry-leading molecular glue degrader platform, has been the cornerstone for Monte Rosa’s success, driving the discovery and development of our exquisitely selective MGDs successfully into the clinic. This collaboration will enable and accelerate expansion of our platform into neuroscience and additional areas of oncology. We believe our decision to partner with Roche, a company that shares our vision and drive, will amplify our collective strengths and capabilities to accelerate the development of transformative treatments for patients across several indications,” said Markus Warmuth, M.D., CEO of Monte Rosa Therapeutics.
James Sabry, M.D., Ph.D., Global Head of Pharma Partnering at Roche, added: “We believe that molecular glue degraders are a powerful new class of small molecules that target disease-related proteins that traditional approaches have been unable to address. Together with Monte Rosa, we look forward to tackling high-value targets in both oncology and neuroscience with the goal of unlocking new therapeutic possibilities.”
Under the terms of the agreement, Monte Rosa Therapeutics will receive an upfront payment of $50 million, and is eligible to receive future preclinical, clinical, commercial and sales milestone payments that could exceed $2 billion, as well as tiered royalties. The parties also agreed on a mechanism to expand the collaboration on multiple targets within the first two years. In that case, additional payments for nomination, preclinical, clinical, commercial and sales milestones are due, as well as tiered royalties on the resulting products. Monte Rosa Therapeutics will lead discovery and preclinical activities against multiple select cancer and neurological disease targets to a defined point. Roche gains the right to exclusively pursue further preclinical and clinical development of the compounds. Monte Rosa retains full ownership of its pipeline programs.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond. For more information, visit www.monterosatx.com
SOURCE: Monte Rosa Therapeutics
Post Views: 533
Collaboration combines Monte Rosa Therapeutics’ highly differentiated QuEENTM discovery engine with Roche’s strong expertise in delivering transformative therapies to patients
Monte Rosa to receive an upfront payment of $50 million and potential future payments exceeding $2 billion
BOSTON, MA, USA I October 17, 2023 IMonte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced it has entered into a strategic collaboration and licensing agreement with global healthcare leader Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug.
“We are excited to partner with Roche, a leading healthcare and one of the world’s top oncology companies. Our QuEEN™ discovery engine, a highly validated and industry-leading molecular glue degrader platform, has been the cornerstone for Monte Rosa’s success, driving the discovery and development of our exquisitely selective MGDs successfully into the clinic. This collaboration will enable and accelerate expansion of our platform into neuroscience and additional areas of oncology. We believe our decision to partner with Roche, a company that shares our vision and drive, will amplify our collective strengths and capabilities to accelerate the development of transformative treatments for patients across several indications,” said Markus Warmuth, M.D., CEO of Monte Rosa Therapeutics.
James Sabry, M.D., Ph.D., Global Head of Pharma Partnering at Roche, added: “We believe that molecular glue degraders are a powerful new class of small molecules that target disease-related proteins that traditional approaches have been unable to address. Together with Monte Rosa, we look forward to tackling high-value targets in both oncology and neuroscience with the goal of unlocking new therapeutic possibilities.”
Under the terms of the agreement, Monte Rosa Therapeutics will receive an upfront payment of $50 million, and is eligible to receive future preclinical, clinical, commercial and sales milestone payments that could exceed $2 billion, as well as tiered royalties. The parties also agreed on a mechanism to expand the collaboration on multiple targets within the first two years. In that case, additional payments for nomination, preclinical, clinical, commercial and sales milestones are due, as well as tiered royalties on the resulting products. Monte Rosa Therapeutics will lead discovery and preclinical activities against multiple select cancer and neurological disease targets to a defined point. Roche gains the right to exclusively pursue further preclinical and clinical development of the compounds. Monte Rosa retains full ownership of its pipeline programs.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond. For more information, visit www.monterosatx.com
SOURCE: Monte Rosa Therapeutics
Post Views: 533
